Natera, which sells non-invasive prenatal disease screening tests, raised the proposed deal size for its upcoming IPO on Wednesday. The San Carlos, CA-based company now plans to raise $175 million by offering 10 million shares at a price range of $17 to $18. The company had previously filed to offer 6 million shares at a range of $15 to $17. At the midpoint of the revised range, Natera would raise 75% more than previously anticipated.
Natera, which was founded in 2003 and booked $179 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol NTRA. Natera initially filed confidentially on 5/14/2014. Morgan Stanley, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of June 29, 2015.
